shorts won't be happy Mon when bounce comes an we go over $8 again.
great article.. drug only been sold for 2 months..will be big winner.
Seeking Alpha (Saturday )
5 Stocks To Watch For Gains This Week
Mar 30 2013 By: Brian Nichols
The drug, as currently approved, has market potential around $1 billion, judging by the success of Lovaza. Due to the success of its trial ANCHOR and the market potential of elevated triglyceride levels, which is eight times larger, I am not sure how Amarin is not a buy right now for the long term, in addition to short term. Assuming its indication is expanded, as I believe it will, I think the market is large enough for a bare minimum $1 billion in sales. Therefore, with the stock being very oversold, I wouldn't be surprised to see pop off its current bottom range next week. In addition, if $1 billion in sales is achieved (minimum) then the typical 3-4 times sales should also be expected, therefore presenting great upside.
Seeking Alpha By: Briam Wilson 3/26/13
Pimavanserin is an inverse agonist of the serotonin receptor 5-HT2A. Molecules working through the same mechanism of action have had limited success so far, which is why pimavanserin in a particularly attractive molecule right now that may pique the interest of other pharmaceutical companies interested in expansion of their psychotic drug pipelines.
This, combined with Acadia's (still) low market capitalization of ~$660 million (at the time of writing) makes
Acadia a prime acquisition target for big pharmaceutical companies, particular those that are struggling with their top-line growth.
Seeking Alpha By: Brian Nichlos 3/25/13
Last week there were several big-time performances in the small cap biotechnology space. While I view each stock differently, I do acknowledge that at this point, all have great upside potential. In my opinion, ACADIA is the safest,
nice run up today.
I am In